Sign in

You're signed outSign in or to get full access.

Alex Riesemann

Research Analyst at Piper Sandler & Co.

Alex Riesemann is an Equity Research Analyst at Piper Sandler Companies, specializing in coverage of pharmaceutical and biopharmaceuticals with a focus on firms such as Xeris Biopharma and Supernus Pharmaceuticals. He has contributed to investor discussions around quarterly earnings, providing analysis on financial performance and growth metrics for covered companies. Riesemann joined Piper Sandler following earlier roles in financial analysis and equity research, establishing his expertise within the healthcare sector over several years. He holds industry-standard professional credentials including relevant FINRA registrations and securities licenses, underscoring his qualifications as a research analyst.

Alex Riesemann's questions to Xeris Biopharma Holdings (XERS) leadership

Question · Q2 2025

Alex Riesemann from Piper Sandler Companies asked about the long-term spending strategy for RECORLEV, including any plans for near-term headcount or promotional expansion, and whether the company intends to target general practitioners.

Answer

CEO John Shannon reiterated the company's commitment, first outlined at its June Investor Day, to continue investing significantly in RECORLEV. He confirmed that Xeris has already begun the process of increasing its commercial footprint to support the product's dynamic growth and will continue making substantial investments over the next several years to build the brand.

Ask follow-up questions

Fintool

Fintool can predict Xeris Biopharma Holdings logo XERS's earnings beat/miss a week before the call

Alex Riesemann's questions to SUPERNUS PHARMACEUTICALS (SUPN) leadership

Question · Q2 2025

Alex Riesemann of Piper Sandler requested details on the commercial infrastructure supporting ZERZUVEY, including sales force headcount, the number of practitioners being targeted, and any planned changes from Sage's strategy.

Answer

CEO Jack Khattar stated that he was not at liberty to discuss the specifics of the ZERZUVEY commercial infrastructure. He explained that such details would need to be discussed with their partner, Biogen, before any public disclosure could be made, but that they may provide color at a later date.

Ask follow-up questions

Fintool

Fintool can predict SUPERNUS PHARMACEUTICALS logo SUPN's earnings beat/miss a week before the call

Alex Riesemann's questions to Organon & (OGN) leadership

Question · Q2 2025

Alex Riesemann of Piper Sandler Companies inquired about future sales and marketing investments for VITAMMA, specifically asking about direct-to-consumer (DTC) campaigns, sales force expansion, and the current number of practitioners and reps supporting the product.

Answer

Kevin Ali, CEO & Board Member of Organon, confirmed that new telehealth and DTC campaigns, along with pediatric-focused initiatives, began in July. He stated the company feels comfortable with its second-half investment plans and has expanded its sales force to over 125 representatives to support VITAMMA's growth.

Ask follow-up questions

Fintool

Fintool can predict Organon & logo OGN's earnings beat/miss a week before the call